Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Doroshow, JH' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 70 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Margolin, K; Synold, T; Longmate, J; Doroshow, JH
      Methodologic guidelines for the design of high-dose chemotherapy regimens

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    2. Somlo, G; Chow, W; Hamasaki, V; Leong, L; Margolin, K; Morgan, R; Sniecinski, I; Frankel, P; Reardon, D; Longmate, J; Raschko, J; Shibata, S; O'Donnell, M; Smith, E; Tetef, M; Forman, S; Yen, Y; Molina, A; Doroshow, JH
      Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    3. Tetef, ML; Synold, TW; Chow, W; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Yen, Y; Groshen, S; Johnson, K; Lenz, HJ; Gandara, D; Doroshow, JH
      Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies

      CLINICAL CANCER RESEARCH
    4. Lara, PN; Gandara, DR; Longmate, J; Gumerlock, PH; Martin, DHML; Edelman, J; Gandour-Edwards, R; Mack, PC; Israel, V; Raschko, J; Frankel, P; Perez, EA; Lenz, HJ; Doroshow, JH
      Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    5. Morgan, RJ; Synold, T; Carr, BI; Doroshow, JH; Womack, EP; Shibata, S; Somlo, G; Raschko, J; Leong, L; McNamara, M; Chow, W; Tetef, M; Margolin, K; Akman, S; Longmate, J
      Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    6. Morgan, RJ; Doroshow, JH; Leong, L; Schriber, J; Shibata, S; Forman, S; Hamasaki, V; Margolin, K; Somlo, G; Alvarnas, J; McNamara, M; Longmate, J; Raschko, J; Chow, W; Vasilev, S; McGonigle, K; Yen, Y
      Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

      BONE MARROW TRANSPLANTATION
    7. Esworthy, RS; Aranda, R; Martin, MG; Doroshow, JH; Binder, SW; Chu, FF
      Mice with combined disruption of Gpx1 and Gpx2 genes have colitis

      AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
    8. Margolin, K; Longmate, J; Synold, TW; Gandara, DR; Weber, J; Gonzalez, R; Johansen, MJ; Newman, R; Baratta, T; Doroshow, JH
      Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium

      INVESTIGATIONAL NEW DRUGS
    9. Somlo, G; Doroshow, JH; Synold, T; Longmate, J; Reardon, D; Chow, W; Forman, SJ; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Shibata, SI; Tetef, ML; Yen, Y; Kogut, N; Schriber, J; Alvarnas, J
      High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome

      BRITISH JOURNAL OF CANCER
    10. List, AF; Kopecky, KJ; Willman, CL; Head, DR; Persons, DL; Slovak, ML; Dorr, R; Karanes, C; Hynes, HE; Doroshow, JH; Shurafa, M; Appelbaum, FR
      Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

      BLOOD
    11. Doroshow, JH; Synold, TW; Somlo, G; Akman, SA; Gajewski, E
      Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin

      BLOOD
    12. Kane, SE; Matsumoto, L; Metz, MZ; Donohue, CA; Lingeman, RG; Lin, SW; Doroshow, JH
      MDR1 bicistronic vectors: analysis of selection stringency, amplified geneexpression, and vector stability in cell lines

      BIOCHEMICAL PHARMACOLOGY
    13. Wong, JYC; Chu, DZ; Yamauchi, DM; Williams, LE; Liu, A; Wilczynski, S; Wu, AM; Shively, JE; Doroshow, JH; Raubitschek, AA
      A phase I radioimmunotherapy trial evaluating (90)yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84,66 in patients with metastatic CEA-producing malignancies

      CLINICAL CANCER RESEARCH
    14. Engstrom, PF; Benson, A; Choti, MA; Cohen, AM; Doroshow, JH; Fuchs, C; Kiel, K; Martin, EW; McGinn, C; Petrelli, NJ; Posey, JA; Skibber, JM; Venook, A; Yeatman, TJ
      NCCN Practice Guidelines for colorectal cancer

      ONCOLOGY-NEW YORK
    15. Raschko, JW; Synold, TW; Chow, W; Coluzzi, P; Hamasaki, V; Leong, LA; Margolin, KA; Morgan, RJ; Shibata, SI; Somlo, G; Tetef, ML; Yen, Y; ter Veer, A; Doroshow, JH
      A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    16. Tetef, ML; Margolin, KA; Doroshow, JH; Akman, S; Leong, LA; Morgan, RJ; Raschko, JW; Slatkin, N; Somlo, G; Longmate, JA; Carroll, MI; Newman, EM
      Pharmacokinetics and toxicity of high-dose intravenous methotrexate in thetreatment of leptomeningeal carcinomatosis

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    17. Morgan, RJ; Braly, P; Leong, L; Shibata, S; Margolin, K; Somlo, G; McNamara, M; Longmate, J; Schinke, S; Raschko, J; Nagasawa, S; Kogut, N; Najera, L; Johnson, D; Doroshow, JH
      Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up

      GYNECOLOGIC ONCOLOGY
    18. Wong, JYC; Somlo, G; Odom-Maryon, T; Williams, LE; Liu, A; Yamauchi, D; Wu, AM; Yazaki, P; Wilczynski, S; Shively, JE; Forman, S; Doroshow, JH; Raubitschek, AA
      Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer

      CLINICAL CANCER RESEARCH
    19. Tetef, M; Leong, L; Ahn, C; Akman, S; Chow, W; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Doroshow, JH
      Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial

      CANCER INVESTIGATION
    20. Morgan, RJ; Braly, P; Cecchi, G; Leong, L; Shibata, S; Margolin, K; Somlo, G; McNamara, M; Longmate, J; Schinke, S; Raschko, J; Nagasawa, S; Kogut, N; Parker, P; Stein, A; Cho, J; Smith, E; Coluzzi, P; Najera, L; Johnson, D; Womack, E; Doroshow, JH
      Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up

      GYNECOLOGIC ONCOLOGY
    21. Leichman, CG; Jacobson, JR; Modiano, M; Daniels, JR; Zalupski, MM; Doroshow, JH; Fletcher, WS; Macdonald, JS
      Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma - A Southwest Oncology Group pilot trial

      CANCER
    22. Somlo, G; Sniecinski, I; ter Veer, A; Longmate, J; Knutson, G; Vuk-Pavlovic, S; Bhatia, R; Chow, W; Leong, L; Morgan, R; Margolin, K; Raschko, J; Shibata, S; Tetef, M; Yen, Y; Forman, S; Jones, D; Ashby, M; Fyfe, G; Hellmann, S; Doroshow, JH
      Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy

      BLOOD
    23. SYNOLD TW; NEWMAN EM; CARROLL M; MUGGIA FM; GROSHEN S; JOHNSON K; DOROSHOW JH
      CELLULAR BUT NOT PLASMA PHARMACOKINETICS OF LOMETREXOL CORRELATE WITHTHE OCCURRENCE OF CUMULATIVE HEMATOLOGICAL TOXICITY

      Clinical cancer research
    24. YAM PY; YEE JK; ITO JI; SNIECINSKI I; DOROSHOW JH; FORMAN SJ; ZAIA JA
      COMPARISON OF AMPHOTROPIC AND PSEUDOTYPED VSV-G RETROVIRAL TRANSDUCTION IN HUMAN CD34(-BLOOD PROGENITOR CELLS FROM ADULT DONORS WITH HIV-1 INFECTION OR CANCER() PERIPHERAL)

      Experimental hematology
    25. SYNOLD TW; TETEF ML; DOROSHOW JH
      ANTINEOPLASTIC ACTIVITY OF CONTINUOUS EXPOSURE TO DEXRAZOXANE - POTENTIAL NEW ROLE AS A NOVEL TOPOISOMERASE-II INHIBITOR

      Seminars in oncology
    26. MORGAN RJ; NEWMAN EM; DOROSHOW JH; MCGONIGLE K; MARGOLIN K; RASCHKO J; CHOW W; SOMLO G; LEONG L; TETEF M; SHIBATA S; HAMASAKI V; CARROLL M; VASILEV S; AKMAN S; COLUZZI P; WAGMAN L; LONGMATE J; PAZ B; YEN Y; KLEVECZ R
      PHASE-I TRIAL OF INTRAPERITONEAL IODODEOXYURIDINE WITH AND WITHOUT INTRAVENOUS HIGH-DOSE FOLINIC ACID IN THE TREATMENT OF ADVANCED MALIGNANCIES PRIMARILY CONFINED TO THE PERITONEAL-CAVITY - FLOW CYTOMETRIC ANDPHARMACOKINETIC ANALYSIS

      Cancer research
    27. MORGAN RJ; DOROSHOW JH; VENKATARAMAN K; CHANG K; RASCHKO J; SOMLO G; LEONG L; TETEF M; SHIBATA S; HAMASAKI V; MARGOLIN K; FORMAN S; AKMAN S; COLUZZI P; AHN C; WEISS L; GADGIL U; HARRISON J
      HIGH-DOSE INFUSIONAL DOXORUBICIN AND CYCLOPHOSPHAMIDE - A FEASIBILITYSTUDY OF TANDEM HIGH-DOSE CHEMOTHERAPY CYCLES WITHOUT STEM-CELL SUPPORT

      Clinical cancer research
    28. SOSMAN JA; ARONSON FR; SZNOL M; ATKINS MB; DUTCHER JP; WEISS GR; ISAACS RE; MARGOLIN KA; FISHER RI; ERNEST ML; MIER J; OLEKSOWICZ L; ECKHARDT JR; LEVITT D; DOROSHOW JH
      CONCURRENT PHASE-I TRIALS OF INTRAVENOUS INTERLEUKIN-6 IN SOLID TUMORPATIENTS - REVERSIBLE DOSE-LIMITING NEUROLOGICAL TOXICITY

      Clinical cancer research
    29. HERSH EM; STOPECK AT; SILVER HKB; CHANG AE; DOROSHOW JH; RUBIN J; RHINEHART J; STAHL SM; SCHREIBER AB
      PHASE-II STUDY OF INTRATUMORAL INJECTION OF HLA-B7 BETA-2M PLASMID DNA-CATIONIC LIPID COMPLEX (ALLOVECTIN-7) THERAPY FOR METASTATIC MALIGNANT-MELANOMA (MMM)/

      Cancer gene therapy
    30. SOMLO G; DOROSHOW JH; FORMAN SJ; ODOMMARYON T; LEE J; CHOW W; HAMASAKI V; LEONG L; MORGAN R; MARGOLIN K; RASCHKO J; SHIBATA S; TETEF M; YEN Y; SIMPSON J; MOLINA A
      HIGH-DOSE CHEMOTHERAPY AND STEM-CELL RESCUE IN THE TREATMENT OF HIGH-RISK BREAST-CANCER - PROGNOSTIC INDICATORS OF PROGRESSION-FREE AND OVERALL SURVIVAL

      Journal of clinical oncology
    31. NEWMAN EM; CARROLL M; AKMAN SA; CHOW W; COLUZZI P; HAMASAKI V; LEONG LA; MARGOLIN KA; MORGAN RJ; RASCHKO JW; SHIBATA S; SOMLO G; TETEF M; YEN Y; AHN CW; DOROSHOW JH
      PHARMACOKINETICS AND TOXICITY OF 120-HOUR CONTINUOUS-INFUSION HYDROXYUREA IN PATIENTS WITH ADVANCED SOLID TUMORS

      Cancer chemotherapy and pharmacology
    32. YAM PY; YEE JK; ITO JI; SNIECINSKI I; DOROSHOW JH; FORMAN SJ; ZAIA JA
      AMPHOTROPIC AND PSEUDOTYPED VSV-G RETROVIRAL TRANSDUCTION OF CD34-CELLS (HSC) - COMPARISON IN HSC FROM HIV-1-INFECTED AND NONINFECTED SOURCES( HEMATOPOIETIC STEM)

      Blood
    33. SOMLO G; SNIECINSKI I; BRENT J; TERVEER A; CHOW W; FORMAN S; HAMASAKI V; LEONG L; MORGAN R; MARGOLIN K; RADER D; RASCHKO J; SHIBATA S; TETEF M; YEN Y; MOLINA A; ASHBY M; JONES D; DOROSHOW JH
      RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH G-CSF ISSAFE AND EFFECTIVE AS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) MOBILIZER

      Blood
    34. SOMLO G; SNIECINSKI I; ODOMMARYON T; NOWICKI B; CHOW W; HAMASAKI V; LEONG L; MARGOLIN K; MORGAN R; RASCHKO J; SHIBATA S; TETEF M; MOLINA A; BERENSON RJ; FORMAN SJ; DOROSHOW JH
      EFFECT OF CD34(-CELL REINFUSION AND GRANULOCYTE-COLONY-STIMULATING FACTOR PRIMING ON HEMATOPOIETIC RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER() SELECTION AND VARIOUS SCHEDULES OF STEM)

      Blood
    35. SYNOLD TW; XI BX; NEWMAN EM; MUGGIA FM; DOROSHOW JH
      SIMPLE AND SENSITIVE METHOD FOR THE QUANTITATIVE-ANALYSIS OF LOMETREXOL IN PLASMA USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION

      Journal of chromatography B. Biomedical applications
    36. MARGOLIN K; DOROSHOW JH; AHN C; HAMASAKI V; LEONG L; MORGAN R; RASCHKO J; SHIBATA S; SOMLO G; TETEF M
      TREATMENT OF GERM-CELL CANCER WITH 2 CYCLES OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE WITH AUTOLOGOUS STEM-CELL SUPPORT

      Journal of clinical oncology
    37. METZ MZ; MATSUMOTO L; WINTERS KA; DOROSHOW JH; KANE SE
      BICISTRONIC AND 2-GENE RETROVIRAL VECTORS FOR USING MDR1 AS A SELECTABLE MARKER AND A THERAPEUTIC GENE

      Virology
    38. DOROSHOW JH
      BIOCHEMICAL MODULATION OF FLUOROPYRIMIDINES - IS THERE AN OPTIMAL (6R,S)LEUCOVORIN DOSE AND SCHEDULE

      Journal of the National Cancer Institute
    39. MUGGIA FM; SYNOLD TW; NEWMAN EM; JEFFERS S; LEICHMAN LP; DOROSHOW JH; JOHNSON K; GROSHEN S
      FAILURE OF PRETREATMENT WITH INTRAVENOUS FOLIC-ACID TO ALTER THE CUMULATIVE HEMATOLOGIC TOXICITY OF LOMETREXOL

      Journal of the National Cancer Institute
    40. WEISS GR; MARGOLIN KA; SZNOL M; ATKINS MB; OLEKSOWICZ L; ISAACS R; SOSMAN JA; DOROSHOW JH; TREHU EG; DUTCHER JP; FISHER RI
      A PHASE-II STUDY OF THE CONTINUOUS INTRAVENOUS-INFUSION OF INTERLEUKIN-6 FOR METASTATIC RENAL-CELL CARCINOMA

      Journal of immunotherapy with emphasis on tumor immunology
    41. WELBORN JL; KOPECKY KJ; MEYERS FJ; VEITH R; SHURAFA M; DOROSHOW JH; BALCERZAK SP; APPELBAUM FR
      CARBOPLATIN INFUSION IN RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA - A SOUTHWEST-ONCOLOGY-GROUP TRIAL

      Leukemia
    42. MORGAN RJ; MARGOLIN K; RASCHKO J; AKMAN S; LEONG L; SOMLO G; SCANLON K; AHN C; CARROLL M; DOROSHOW JH
      PHASE-I TRIAL OF CARBOPLATIN AND INFUSIONAL CYCLOSPORINE IN ADVANCED MALIGNANCY

      Journal of clinical oncology
    43. LEICHMAN CG; FLEMING TR; MUGGIA FM; TANGEN CM; ARDALAN B; DOROSHOW JH; MEYERS FJ; HOLCOMBE RF; WEISS GR; MANGALIK A; MACDONALD JS
      PHASE-II STUDY OF FLUOROURACIL AND ITS MODULATION IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

      Journal of clinical oncology
    44. SOMLO G; DOROSHOW JH; LEVRAN A; AHN DC; HWANG L; RASCHKO JW; FORMAN SJ; MARGOLIN KA; MORGAN RJ; LEONG LA; HAMASAKI VK; CHOW WA; MOLINA A; AHMAD B; AKMAN SA; KOJIAN A; MENARD P
      EFFECT OF LOW-DOSE PROPHYLACTIC DOPAMINE ON HIGH-DOSE CISPLATIN-INDUCED ELECTROLYTE WASTING, OTOTOXICITY, AND EPIDERMAL GROWTH-FACTOR EXCRETION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL

      Journal of clinical oncology
    45. COLUZZI PH; GRANT M; DOROSHOW JH; RHINER M; FERRELL B; RIVERA L
      SURVEY OF THE PROVISION OF SUPPORTIVE CARE SERVICES AT NATIONAL-CANCER-INSTITUTE - DESIGNATED CANCER CENTERS

      Journal of clinical oncology
    46. DOROSHOW JH
      GLUTATHIONE-PEROXIDASE AND OXIDATIVE STRESS

      Toxicology letters
    47. MARGOLIN KA; AKMAN SA; LEONG LA; MORGAN RJ; SOMLO G; RASCHKO JW; AHN C; DOROSHOW JH
      PHASE-I STUDY OF MITOMYCIN-C AND MENADIONE IN ADVANCED SOLID TUMORS

      Cancer chemotherapy and pharmacology
    48. ERKMEN K; EGORIN MJ; REYNO LM; MORGAN R; DOROSHOW JH
      EFFECTS OF STORAGE ON THE BINDING OF CARBOPLATIN TO PLASMA-PROTEINS

      Cancer chemotherapy and pharmacology
    49. TETEF M; MARGOLIN K; AHN C; AKMAN S; CHOW W; COLUZZI P; LEONG L; MORGAN RJ; RASCHKO J; SHIBATA S; SOMLO G; DOROSHOW JH
      MITOMYCIN-C AND MENADIONE FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL CANCERS - A PHASE-II TRIAL

      Journal of cancer research and clinical oncology
    50. TETEF M; MARGOLIN K; AHN C; AKMAN S; CHOW W; LEONG L; MORGAN RJ; RASCHKO J; SOMLO G; DOROSHOW JH
      MITOMYCIN-C AND MENADIONE FOR THE TREATMENT OF LUNG-CANCER - A PHASE-II TRIAL

      Investigational new drugs
    51. MORGAN RJ; SPEYER J; DOROSHOW JH; MARGOLIN K; RASCHKO J; SORICH J; AKMAN S; LEONG L; SOMLO G; VASILEV S; AHN C; JOHNSON D; BELLER U
      MODULATION OF 5-FLUOROURACIL WITH HIGH-DOSE LEUCOVORIN CALCIUM - ACTIVITY IN OVARIAN-CANCER AND CORRELATION WITH CA-125 LEVELS

      Gynecologic oncology
    52. RODRIGUEZ H; DROUIN R; HOLMQUIST GP; OCONNOR TR; BOITEUX S; LAVAL J; DOROSHOW JH; AKMAN SA
      MAPPING OF COPPER HYDROGEN PEROXIDE-INDUCED DNA-DAMAGE AT NUCLEOTIDE RESOLUTION IN HUMAN GENOMIC DNA BY LIGATION-MEDIATED POLYMERASE CHAIN-REACTION

      The Journal of biological chemistry
    53. ZHOU BS; HSU NY; PAN BC; DOROSHOW JH; YEN Y
      OVEREXPRESSION OF RIBONUCLEOTIDE REDUCTASE IN TRANSFECTED HUMAN KB CELLS INCREASES THEIR RESISTANCE TO HYDROXYUREA - M2 BUT NOT M1 IS SUFFICIENT TO INCREASE RESISTANCE TO HYDROXYUREA IN TRANSFECTED CELLS

      Cancer research
    54. DOROSHOW JH; METZ MZ; MATSUMOTO L; WINTERS KA; SAKAI M; MURAMATSU M; KANE SE
      TRANSDUCTION OF NIH 3T3 CELLS WITH A RETROVIRUS CARRYING BOTH HUMAN MDR1 AND GLUTATHIONE-S-TRANSFERASE-PI PRODUCES BROAD-RANGE MULTIDRUG-RESISTANCE

      Cancer research
    55. MEYSKENS FL; KOPECKY KJ; TAYLOR CW; NOYES RD; TUTHILL RJ; HERSH EM; FEUN LG; DOROSHOW JH; FLAHERTY LE; SONDAK VK
      RANDOMIZED TRIAL OF ADJUVANT HUMAN INTERFERON-GAMMA VERSUS OBSERVATION IN HIGH-RISK CUTANEOUS MELANOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY

      Journal of the National Cancer Institute
    56. SPARANO JA; FISHER RI; WEISS GR; MARGOLIN K; ARONSON FR; HAWKINS MJ; ATKINS MB; DUTCHER JP; GAYNOR ER; BOLDT DH; DOROSHOW JH; ERNEST ML; SZNOL M; MIER JW
      PHASE-II TRIALS OF HIGH-DOSE INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS IN ADVANCED BREAST-CARCINOMA AND CARCINOMA OF THE LUNG, OVARY, AND PANCREAS AND OTHER TUMORS

      Journal of immunotherapy with emphasis on tumor immunology
    57. MARGOLIN K; ARONSON FR; SZNOL M; ATKINS MB; GUCALP R; FISHER RI; SUNDERLAND M; DOROSHOW JH; ERNEST ML; MIER JW; DUTCHER JP; GAYNOR ER; WEISS GR
      PHASE-II STUDIES OF RECOMBINANT HUMAN INTERLEUKIN-4 IN ADVANCED RENAL-CANCER AND MALIGNANT-MELANOMA

      Journal of immunotherapy with emphasis on tumor immunology
    58. HAWKINS MJ; ATKINS MB; DUTCHER JP; FISHER RI; WEISS GR; MARGOLIN KA; RAYNER AA; SZNOL M; PARKINSON DR; PAIETTA E; GAYNOR ER; BOLDT DH; DOROSHOW JH; ARONSON FR
      A PHASE-II CLINICAL-TRIAL OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS IN ADVANCED COLORECTAL-CARCINOMA

      Journal of immunotherapy with emphasis on tumor immunology
    59. ESWORTHY RS; DOROSHOW JH; CHU FF
      EXPRESSION OF THE GSHPX-GI ISOZYME OF SELENIUM-DEPENDENT GLUTATHIONE-PEROXIDASE IN THE TISSUES OF MAN AND RODENTS

      The FASEB journal
    60. ESWORTHY RS; DOAN K; DOROSHOW JH; CHU FF
      CLONING AND SEQUENCING OF THE CDNA-ENCODING A HUMAN TESTIS PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE-PEROXIDASE

      Gene
    61. RASCHKO JW; AKMAN SA; LEONG LA; MARGOLIN KA; MORGAN RJ; NEWMAN E; SOMLO G; AHN C; DOROSHOW JH
      PHASE-I STUDY OF 5-DAY CONTINUOUS-INFUSION FLUORODEOXYURIDINE AND HIGH-DOSE FOLINIC ACID WITH ORAL HYDROXYUREA

      Cancer chemotherapy and pharmacology
    62. MARGOLIN KA; GREEN S; OSBORNE K; DOROSHOW JH; AKMAN SA; LEONG LA; MORGAN RJ; RASCHKO JW; SOMLO G; HUTCHINS L; UPCHURCH C
      PHASE-II TRIAL OF 5-FLUOROURACIL AND HIGH-DOSE FOLINIC ACID AS 1ST-LINE OR 2ND-LINE THERAPY FOR ADVANCED BREAST-CANCER

      American journal of clinical oncology
    63. RAVDIN PM; GREEN S; DOROSHOW JH; MARTINO S
      PHASE-II TRIAL OF PIROXANTRONE IN METASTATIC BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

      Investigational new drugs
    64. SOMLO G; DOROSHOW JH; FORMAN SJ; LEONG LA; MARGOLIN KA; MORGAN RJ; RASCHKO JW; AKMAN SA; AHN C; NAGASAWA S; HARRISON J; STEIN A; SMITH E; SNIECINSKI I; SCHMIDT GM
      HIGH-DOSE DOXORUBICIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE WITH STEM-CELLREINFUSION IN PATIENTS WITH METASTATIC OR HIGH-RISK PRIMARY BREAST-CANCER

      Cancer
    65. SOMLO G; DOROSHOW JH; FORMAN SJ; LEONG LA; MARGOLIN KA; MORGAN RJ; RASCHKO JW; AKMAN SA; AHN C; SNIECINSKI I
      HIGH-DOSE CISPLATIN, ETOPOSIDE, AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS STEM-CELL REINFUSION IN PATIENTS WITH RESPONSIVE METASTATIC OR HIGH-RISK PRIMARY BREAST-CANCER

      Cancer
    66. MARGOLIN KA; DOROSHOW JH; AKMAN SA; LEONG LA; MORGAN R; RASCHKO J; SOMLO G; DUTCHER J; HAWKSWORTH K; YONEMOTO L; CALIENDO G; CAVASOTTO G
      PHASE-I TRIAL OF INTERLEUKIN-2 PLUS DOXORUBICIN

      Journal of immunotherapy with emphasis on tumor immunology
    67. ANTMAN K; CROWLEY J; BALCERZAK SP; RIVKIN SE; WEISS GR; ELIAS A; NATALE RB; COOPER RM; BARLOGIE B; TRUMP DL; DOROSHOW JH; AISNER J; PUGH RP; WEISS RB; COOPER BA; CLAMOND GH; BAKER LH
      AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS

      Journal of clinical oncology
    68. SPARANO JA; FISHER RI; SUNDERLAND M; MARGOLIN K; ERNEST ML; SZNOL M; ATKINS MB; DUTCHER JP; MICETICH KC; WEISS GR; DOROSHOW JH; ARONSON FR; RUBINSTEIN LV; MIER JW
      RANDOMIZED PHASE-III TRIAL OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED MELANOMA

      Journal of clinical oncology
    69. AKMAN SA; KENSLER TW; DOROSHOW JH; DIZDAROGLU M
      COPPER ION-MEDIATED MODIFICATION OF BASES IN DNA IN-VITRO BY BENZOYL PEROXIDE

      Carcinogenesis
    70. ESWORTHY RS; CHU FF; GEIGER P; GIROTTI AW; DOROSHOW JH
      REACTIVITY OF PLASMA GLUTATHIONE-PEROXIDASE WITH HYDROPEROXIDE SUBSTRATES AND GLUTATHIONE

      Archives of biochemistry and biophysics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 18:35:10